There is a single number that explains why U.S. API reshoring is going to be harder than the press releases suggest.
Ten percent.
That is the approximate share of active pharmaceutical ingredients in U.S. prescription drugs that are actually manufactured in the United States today, according to the August 13, 2025 executive order signed by the Trump administration directing the Strategic Active Pharmaceutical Ingredients Reserve. The same order set a target of building a six-month domestic API stockpile for approximately 26 drugs deemed essential to national health and security.
The number behind the policy is even more stark. More than 80 of the top 100 generic medicines prescribed in the United States have no U.S.-based source for their active pharmaceutical ingredients, according to research from the Olin Business School at Washington University in St. Louis cited in BioSpace. The therapeutic categories most exposed include anesthetics, chemotherapies, and antibiotics, where supply disruptions become public health emergencies within weeks.
The industry’s response has been the largest commitment of capital to domestic pharmaceutical manufacturing in modern history. AbbVie has announced $380 million in two new API facilities at its North Chicago campus, with construction beginning in spring 2026 and full operations targeted for 2029. Cambrex committed roughly $100 million to expand its Charles City, Iowa API capacity by approximately 40%. Thermo Fisher is expanding its St. Louis API operations and acquired Sanofi’s Ridgefield, New Jersey manufacturing site in 2025 specifically to deepen U.S. capacity. Novartis announced a $23 billion U.S. investment plan that explicitly includes API and biologics drug substance.
The capital is real. The political momentum is real. The site selections are real.
The workforce required to make all of this run is not.
U.S. pharmaceutical workforce growth over the past two decades has been concentrated in biologics manufacturing, formulation, clinical operations, and digital functions. Chemical synthesis and process development, the disciplines that actually run API manufacturing, have been systematically downsized inside major pharma companies and outsourced to contract development and manufacturing organizations (CDMOs).
This is documented in scientific literature, not just industry commentary. A March 2025 perspective published in Angewandte Chemie International Edition by senior process chemists working in the European pharmaceutical industry confirmed the trend. Most pharmaceutical process development departments, the authors noted, have seen significant reductions in internal workforce, with higher reliance on external CDMOs for both routine and specialized synthesis work. The implications for employee skills, the authors observed, are profound, particularly as new chemical modalities require synthesis and purification expertise that many internal teams no longer maintain.
The practical effect is that when a major pharma company announces it will reshore API capacity, the talent it needs to actually run that capacity does not exist inside its own organization. Internal teams have been hollowed out. The expertise sits at CDMOs. And every reshoring project in the U.S. is now competing for talent from the same finite CDMO talent pool.
The gap between announcement and operational capacity in API manufacturing is longer than in almost any other type of industrial reshoring.
DeepCeutix Strategic Briefings, in a February 2026 industry analysis, documented the timing reality directly. A facility breaking ground in 2026 will not produce validated, FDA-approved product until 2029 or 2030 at the earliest. The capital can fund construction. The workforce, quality systems, and validated supply chains take longer to build than the buildings themselves.
This matters because the workforce build cannot start when the facility is ready. It needs to start years before. Process chemists hired in year one of construction need 18 to 24 months of integration with the specific synthesis routes the facility will run. Senior process development scientists need to be embedded in technology transfer from the moment the route is locked. Quality and regulatory affairs teams need to be hiring against PreCheck cohort timelines, which the FDA launched February 1, 2026 with seven participants selected by June 30 of the same year.
Most of the pharma companies announcing major API expansions today have not started those workforce builds. They are still in capital commitment and site selection mode, treating talent as a downstream concern. By the time most realize the workforce problem is upstream, not downstream, the available talent pool will already be locked into competitor projects.
It is tempting to lump API workforce challenges in with the broader pharma manufacturing talent shortage. That comparison underestimates the API problem.
Biologics manufacturing roles, while specialized, draw from a workforce that has been growing in the U.S. for 20 years. North Carolina alone needs 8,000 additional biomanufacturing workers in 2026, per Pharmaceutical Executive, and the educational pipeline through community colleges, university programs, and corporate training partnerships has been steadily building toward that demand. The shortage is real, but the foundation exists.
API manufacturing is different. The educational pipeline for synthetic organic chemists, process development scientists, and chemical engineers with cGMP scale-up experience has been narrowing. Many U.S. universities have shifted chemistry department focus toward biochemistry, materials science, and computational chemistry, reflecting where research funding and academic prestige flowed during the offshoring decades. Process chemistry, the discipline most directly relevant to API reshoring, has been a small and shrinking specialty.
The American Chemical Society’s career guidance reflects this. Pharmaceutical companies prefer PhD chemists for traditional research roles, with B.S. and M.S. chemists more often moving into quality control, regulatory, and adjacent functions. The pipeline of new PhD process chemists entering manufacturing-focused careers has not kept pace with the demand created by reshoring announcements.
The pharma companies that will execute their API reshoring plans on schedule are doing three things differently than the rest.
First, they are treating process chemistry talent acquisition as a multi-year capital program with executive sponsorship, not a quarterly recruiting metric. This means dedicated talent acquisition partners with deep specialty networks, retention investment for senior process chemists at multiples of historical levels, and proactive identification of high-potential mid-career talent for promotion into senior roles within 36 months.
Second, they are building CDMO partnerships intentionally rather than transactionally. The companies that have locked in long-term capacity commitments with the strongest CDMOs, including provisions for talent transfer at facility startup, are de-risking the workforce timeline. Those still treating CDMO relationships as project-by-project procurement decisions are going to find themselves at the back of the queue when the talent crunch hits in 2027 and 2028.
Third, they are aligning geographic strategy with where API talent actually exists. Several of the major reshoring announcements have selected sites based on land cost and tax incentives rather than proximity to existing chemical synthesis talent clusters. Those projects will face longer time-to-staff and higher relocation costs than companies that anchored their site selection in existing talent geography.
The API reshoring buildout is going to define the U.S. pharmaceutical manufacturing landscape for the next decade. The capital allocation decisions are largely made. The political support is in place. The capacity will get built.
The question that determines whether that capacity actually produces validated drug substance on the announced timelines is whether pharma leaders treat the workforce build as a strategic priority of equal weight to the capital build.
Three questions belong on the next operations review for any company with announced API capacity expansion.
First, does the workforce plan match the time horizon of the capital plan, with hiring milestones that begin two to three years before facility validation rather than during it?
Second, has the company built specialty talent partnerships that go beyond traditional staffing relationships, including arrangements with executive search firms and specialized recruiting partners who can compete in a finite, contested labor market?
Third, is process chemistry talent retention being managed as a strategic priority, or is it being treated as a normal HR function in a normal labor market? The latter approach is going to lose people to competitors who are treating it as the former.
The API reshoring story is going to be told two ways in 2030. In one version, the U.S. rebuilt domestic API capacity, restored supply chain resilience, and created a sustainable competitive position in critical medicines manufacturing. In the other version, the factories got built and sat at 60% capacity utilization because the workforce never showed up.
The difference between those two outcomes is not the capital. It is the talent strategy that runs alongside it.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company